...
机译:临床挑战:抗磷脂综合征患者的肝素诱导的II型血小板减少症(HIT II)或假HIT
Institute of Cardiovascular Diseases University Clinical Center of Serbia Pasterova 2 Belgrade 11000 Serbia;
Institute of Cardiovascular Diseases University Clinical Center of Serbia Pasterova 2 Belgrade 11000 Serbia;
Institute of Hematology University Clinical Center of Serbia Koste Todorovica 2 Belgrade Serbia;
Institute of Molecular Genetics and Genetic Engineering Vojvode Stepe 444a Belgrade Serbia;
National Blood Transfusion Institute Svetog Save 39 Belgrade Serbia;
National Blood Transfusion Institute Svetog Save 39 Belgrade Serbia;
National Blood Transfusion Institute Svetog Save 39 Belgrade Serbia;
Institute of Cardiovascular Diseases University Clinical Center of Serbia Pasterova 2 Belgrade 11000 Serbia;
Institute of Molecular Genetics and Genetic Engineering Vojvode Stepe 444a Belgrade Serbia;
Institute of Cardiovascular Diseases University Clinical Center of Serbia Pasterova 2 Belgrade 11000 Serbia;
机译:临床挑战:抗磷脂综合症患者的肝素诱导的II型血小板减少症(HIT II)或假HIT。
机译:肝素诱发的血小板减少症II(HIT-II综合征)的病理形态学方面。
机译:来普鲁德在血液透析中并发肝素诱导的II型血小板减少症(HIT II)的用途—剂量监测
机译:血小板糖蛋白ILB / IIIa抑制剂的长期临床结果与急性冠状动脉综合征患者低分子量肝素联合
机译:涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募,保留和依从性报告。
机译:利伐沙班治疗抗磷脂综合征(RAPS)方案:利伐沙班与华法林在有或无SLE的血栓性抗磷脂综合征患者中进行的前瞻性随机对照II / III期临床试验
机译:使用肝素和血小板糖蛋白IIb-IIIa拮抗剂替罗非班治疗肝素诱导的II型血小板减少症和肾损伤患者体外循环期间的抗凝治疗